{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:57:24Z","timestamp":1780977444630,"version":"3.54.1"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T00:00:00Z","timestamp":1428192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T00:00:00Z","timestamp":1428192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Relapse to addiction following incarceration is common. We estimated the feasibility and effectiveness of extended\u2010release naltrexone (XR\u2010NTX) as relapse prevention among opioid\u2010dependent male adults leaving a large urban jail.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Eight\u2010week, proof\u2010of\u2010concept, open\u2010label, non\u2010blinded randomized effectiveness trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>New York City jails and Bellevue Hospital Center Adult Primary Care clinics, USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      From January 2010 to July 2013, 34 opioid\u2010dependent adult males with no stated interest in agonist treatments (methadone, buprenorphine) received a counseling and referral intervention and were randomized to XR\u2010NTX (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917) versus no medication (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917) within one week prior to jail release.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>\n                      XR\u2010NTX (Vivitrol\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ; Alkermes Inc.), a long\u2010acting injectable mu opioid receptor antagonist.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measures<\/jats:title>\n                    <jats:p>The primary intent\u2010to\u2010treat outcome was post\u2010release opioid relapse at week 4, defined as \u226510\u2009days of opioid misuse by self\u2010report and urine toxicologies. Secondary outcomes were proportion of urine samples negative for opioids and rates of opioid abstinence, intravenous drug use (IVDU), cocaine use, community treatment participation, re\u2010incarceration and overdose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      Acceptance of XR\u2010NTX was high; 15 of 17 initiated treatment. Rates of the primary outcome of week 4 opioid relapse were lower among XR\u2010NTX participants: 38 versus 88% [\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.004; odds ratio (OR)\u2009=\u20090.08, 95% confidence interval (CI)\u2009=\u20090.01\u20130.48]; more XR\u2010NTX urine samples were negative for opioids, 59 versus 29% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.009; OR\u2009=\u20093.5, 95% CI\u2009=\u20091.4\u20138.5). There were no significant differences in the remaining secondary outcomes, including rates of IVDU, cocaine use, re\u2010incarceration and overdose.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Extended\u2010release naltrexone is associated with significantly lower rates of opioid relapse among men in the United States following release from jail when compared with a no medication treatment\u2010as\u2010usual condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.12894","type":"journal-article","created":{"date-parts":[[2015,2,23]],"date-time":"2015-02-23T00:43:19Z","timestamp":1424652199000},"page":"1008-1014","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Opioid treatment at release from jail using extended\u2010release naltrexone: a pilot proof\u2010of\u2010concept randomized effectiveness trial"],"prefix":"10.1111","volume":"110","author":[{"given":"Joshua D.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Population Health New York University School of Medicine  New York NY USA"},{"name":"Department of Medicine, Division of General Internal Medicine New York University School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McDonald","sequence":"additional","affiliation":[{"name":"Department of Population Health New York University School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Grossman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of General Internal Medicine New York University School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McNeely","sequence":"additional","affiliation":[{"name":"Department of Population Health New York University School of Medicine  New York NY USA"},{"name":"Department of Medicine, Division of General Internal Medicine New York University School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Laska","sequence":"additional","affiliation":[{"name":"Department of Psychiatry New York University School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry New York University School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc N.","family":"Gourevitch","sequence":"additional","affiliation":[{"name":"Department of Population Health New York University School of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,5]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.02990.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwr327"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.06.015"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2009.03.002"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03676.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.08.006"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2011.620475"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038335"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2011.620479"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2011.609438"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.04.003"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3181eb3b89"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000313336"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.02.008"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.2.210"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.03.005"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198001000-00006"},{"key":"e_1_2_5_20_1","volume-title":"Alcohol Timeline Followback Users\u2019 Manual","author":"Sobell L. C.","year":"1995"},{"key":"e_1_2_5_21_1","first-page":"281","article-title":"An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors","volume":"10","author":"Navaline H. A.","year":"1994","journal-title":"AIDS Res Hum Retrovir"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199202000-00007"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2011.609446"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2011.616797"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2010.10400696"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.12894","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.12894","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.12894","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.12894","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.12894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:00:51Z","timestamp":1780974051000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.12894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,5]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/add.12894"],"URL":"https:\/\/doi.org\/10.1111\/add.12894","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,5]]},"assertion":[{"value":"2014-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}